<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To explore the value of serum M2-<z:chebi fb="1" ids="15361">pyruvate</z:chebi> kinase (M2-PK) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) mass screening </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We conducted a molecular epidemiology study in Hangzhou, China, from year 2006 to year 2008 </plain></SENT>
<SENT sid="2" pm="."><plain>Serum samples were collected from 93 CRC, 41 advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath>, 137 <z:mpath ids='MPATH_270'>adenomas</z:mpath>, 47 non-<z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath>, and 158 <z:mpath ids='MPATH_458'>normal</z:mpath> participants in a community setting </plain></SENT>
<SENT sid="3" pm="."><plain>Serum M2-PK and carcinoembryonic antigen (CEA) were measured using Enzyme-linked immunosorbent assay </plain></SENT>
<SENT sid="4" pm="."><plain>SPSS 16.0 software was used to perform data analysis </plain></SENT>
<SENT sid="5" pm="."><plain>Area under the receiver operating characteristic curve (AUC), sensitivity, and specificities were estimated for serum M2-PK in diagnosis of colorectal lesions and compared with CEA </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Average serum M2-PK value among 158 <z:mpath ids='MPATH_458'>normal</z:mpath> people was 2.96 U/mL and not affected by gender (P = 0.47) or age (P = 0.59) </plain></SENT>
<SENT sid="7" pm="."><plain>Average serum M2-PK (U/mL) was 14.75 among stage III and 13.10 among stage I and II <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, about 4 times higher than that among <z:mpath ids='MPATH_458'>normal</z:mpath> people </plain></SENT>
<SENT sid="8" pm="."><plain>Average serum M2-PK was 8.58, 6.70, 5.13 and 2.51 U/mL among advanced <z:mpath ids='MPATH_270'>adenoma</z:mpath>, <z:mpath ids='MPATH_270'>adenomas</z:mpath>, non-<z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath>, and <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> patients, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>AUC for serum M2-PK was greater than that for CEA among <z:hpo ids='HP_0000001'>all</z:hpo> colorectal lesions </plain></SENT>
<SENT sid="10" pm="."><plain>AUC for serum M2-PK was 0.89 (0.84, 0.94) (95% confidence interval), higher than that for CEA [0.70 (0.62-0.79)] in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> stage I and II, 0.89 (0.84-0.94) vs 0.73 (0.63-0.83) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> stage III, 0.81 (0.74-0.86) vs 0.63 (0.53 - 0.73) in advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath>, 0.69 (0.64-0.76) vs 0.54 (0.47-0.60) in <z:mpath ids='MPATH_270'>adenomas</z:mpath>, and 0.69 (0.62-0.78) vs 0.58 (0.48-0.68) in non-<z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>The diagnostic sensitivity for <z:hpo ids='HP_0000001'>all</z:hpo> colorectal lesions increased with decrease in the cut-off value of serum M2-PK </plain></SENT>
<SENT sid="12" pm="."><plain>The diagnostic sensitivity (%) of serum M2-PK was 100.00 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, 95.12 advanced <z:mpath ids='MPATH_270'>adenoma</z:mpath>, 82.48 <z:mpath ids='MPATH_270'>adenoma</z:mpath>, and 82.98 non-<z:mpath ids='MPATH_490'>adenomatous polyp</z:mpath> </plain></SENT>
<SENT sid="13" pm="."><plain>There were no <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases missed and 40.51% of unnecessary colonoscopies were avoided when the cut-off value was 2.00 U/mL </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: Serum M2-PK can be used as a primary screening test in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> mass screening </plain></SENT>
<SENT sid="15" pm="."><plain>It may be a promising non-invasive biomarker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> early detection </plain></SENT>
</text></document>